ArticleEmerging infectious diseases2019
Serologic Prevalence of Ebola Virus in Equatorial Africa.
Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Exploring the Use of Viral Vectors Pseudotyped with Viral Glycoproteins as Tools to Study Antibody-Mediated Neutralizing Activity.Microorganisms · 2025Review
- Review
- High Seroreactivities to Orthoebolaviruses in Rural Cameroon: A Case-Control Study on Nonhuman Primate Bites and a Cross-sectional Survey in Rural Populations.The Journal of infectious diseases · 2024Article
- Update on known and emergent viruses affecting human male genital tract and fertility.Basic and clinical andrology · 2024Review
- Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing.Biosensors · 2023Review
- Article
- Pseudotyped Viruses for Marburgvirus and Ebolavirus.Advances in experimental medicine and biology · 2023Article
- Risk Factors for Ebola Exposure in Health Care Workers in Boende, Tshuapa Province, Democratic Republic of the Congo.The Journal of infectious diseases · 2022Article
- Article
- Article
- Assessing the determinants of Ebola virus disease transmission in Baka Community of the Tropical Rainforest of Cameroon.BMC infectious diseases · 2021Article
- More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation.Viruses · 2021Review
- Acute Plasmodium Infection Promotes Interferon-Gamma-Dependent Resistance to Ebola Virus Infection.Cell reports · 2020Article
- Exposure to Ebola Virus and Risk for Infection with Malaria Parasites, Rural Gabon.Emerging infectious diseases · 2020Article
- Seroreactivity against Marburg or related filoviruses in West and Central Africa.Emerging microbes & infections · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
We conducted a serologic survey of 2,430 serum samples collected during 1997-2012 for various studies to determine the prevalence of the hemorrhagic fever virus Ebola virus (EBOV) in equatorial Africa. We screened serum samples for neutralizing antibodies by using a pseudotype microneutralization assay and a newly developed luciferase immunoprecipitation system assay. Specimens seroreactive for EBOV were confirmed by using an ELISA. Our results suggest a serologic prevalence of 2%-3.5% in the Republic of the Congo and the Democratic Republic of the Congo, which have reported outbreaks of infection with EBOV. In addition we detected a seroprevalence of 1.3% in southern Cameroon, which indicated a low risk for exposure in this region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.